目的：探讨玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗对增殖性糖尿病视网膜病变(PDR)患者视网膜出血、视网膜增殖及视力预后的影响。

方法：将我院收治的56例56眼PDR患者分为康柏西普联合微创玻璃体切割术(pars plana vitrectomy，PPV)组和PPV组，各28例，康柏西普组给予玻璃体腔内注射康柏西普+23G微创玻璃体切割术，PPV组仅给予23G微创玻璃体切割术，比较两组手术时间、视网膜出血、视网膜增殖、视力等情况。

结果：康柏西普联合PPV组手术耗时及术中出血量均明显低于PPV组(P<0.05)； 康柏西普联合PPV组术后视力、黄斑厚度均显著优于PPV组(P<0.05)； 康柏西普联合PPV组术后视网膜出血评分、视网膜增殖评分、玻璃体再次出血率及血管内皮生长因子(VEGF)水平均显著低于PPV组(P<0.05)。

结论：玻璃体腔注射康柏西普联合23G微创玻璃体切割术治疗PDR不仅能有效缩短手术时间，减少术中视网膜出血和术后再出血，减轻视网膜增殖，还有助于患者术后视力恢复。

METHODS: Totally 56 cases of PDR patients(56 eyes)admitted to our hospital were randomly divided into the conbercept group(n=28)and the pars plana vitrectomy(PPV)group(n=28). The conbercept group was given intravitreal injection of Conbercept and 23G minimally invasive vitrectomy, and the PPV group was given the 23G minimally invasive vitrectomy only. The operative time, retinal hemorrhage, retinal proliferation and visual acuity were compared between the two groups.

RESULTS: The operative time and intraoperative blood loss in the conbercept group were significantly lower than those in the PPV group(P<0.05). The visual acuity and macula thickness in the conbercept group were significantly better than those in the PPV group(P<0.05). The postoperative retinal hemorrhage score, retinal proliferative score, vitreous rebleeding rate and vascular endothelial growth factor(VEGF)level in the conbercept group were significantly lower than those in the PPV group(P<0.05).

CONCLUSION: Intravitreal injection conbercept combined with 23G minimally invasive vitrectomy for PDR can not only shorten the operative time, reduce the intraoperative retinal hemorrhage and postoperative rebleeding and the retinal proliferation, but also help patients with postoperative visual acuity recovery.